SEARCH

SEARCH BY CITATION

References

  • 1
    Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years. J Urol 1994; 152: 18316
  • 2
    Grossfeld GD, Chang JJ, Broering JM et al. Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPSURE database. J Urol 2000; 163: 11717
  • 3
    Epstein JI, Pound CR, Partin AW, Walsh PC. Disease progression following radical prostatectomy in men with Gleason score 7 tumour. J Urol 1998; 160: 97100
  • 4
    Van Poppel H, Goethuys H, Callewaert P, Vanuytsel L, Van De Voorde W, Baert L. Radical prostatectomy can provide cure for a well-selected clinical stage T3 prostate cancer. Eur Urol 2000; 38: 3729
  • 5
    Vallett BS. Radical perineal prostatectomy subsequent to bilateral orchiectomy. Del State Med J 1944; 16: 1920
  • 6
    Scott WW, Boyd HL. Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate: a retrospective study based upon 25 years of experience. J Urol 1969; 101: 8692
  • 7
    Flamm J, Fischer M, Holtl W, Pflüger H, Toschi W. Complete androgen deprivation prior to radical prostatectomy in patients with stage T3 cancer of the prostate. Eur Urol 1991; 19: 1925
  • 8
    Häggman M, Hellström M, Aus G et al. Neoadjuvant GnRH-agonist treatment (triptorelin and cyproterone acetate for flare protection) and total prostatectomy. Eur Urol 1993; 24: 45660
  • 9
    Scolieri MJ, Altman A, Resnick MI. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review; is it indicated? J Urol 2000; 164: 146572
  • 10
    Aus G, Abrahamsson P-A, Ahlgren G et al. Hormonal treatment before radical prostatectomy: a 3-year follow-up. J Urol 1998; 159: 20137
  • 11
    Klotz LH, Goldenberg SL, Jewett M et al. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group. Urology 1999; 53: 75763
  • 12
    Civantos F, Sadek S, Obek C, Lai S, Soloway M. Neoadjuvant hormonal therapy prior to radical prostatectomy. Mol Urol 1999; 3: 2014
  • 13
    Schulman CC, Debruyne FMJ, Forster G, Selvaggi FP, Zlotta AR, Witjes WPJ. 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2–T3N0M0 prostate cancer. Eur Urol 2000; 38: 70613
  • 14
    TNM. Classification of prostate cancer. In Sobin LH, Wittekind C eds. UICC TNM Classification of Malignant Tumours. New York: Wiley-Liss 1997: 1703
  • 15
    Mostofi FK, Sesterhenn I, Sobin LH. Histologic typing of prostate tumours. In International Histological Classification of Tumours No. 22. Geneva: World Health Organization 1980: 1721
  • 16
    Gleason DF, Mellinger GT and the Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111: 5864
  • 17
    Hugosson J, Abrahamsson P-A, Ahlgren G et al. The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment. Eur Urol 1996; 29: 4139
  • 18
    Amling CL, Bergstrahl EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point? J Urol 2001; 165: 114651
  • 19
    Monfette G, Dupont A, Labrie F. Temporary combination therapy with flutamide and tryptex as adjuvant to radical prostatectomy for the treatment of early stage prostate cancer. In Labrie F, ed. Early Stage Prostate Cancer: Diagnosis and Choice of Therapy. New York: Elsevier Science Publishers 1989: 41–51
  • 20
    Witjes WP, Schulman CC, Debruyne FM. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in, T2–3, N0, M0 prostatic carcinoma. Urology 1997; 49 (Suppl 3A): 659
  • 21
    Labrie F, Cusan L, Gomez J-L et al. Down-staging of early stage prostate cancer before radical prostatectomy: The first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 1994; 44: 2937
  • 22
    Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNXM0) prostate cancer. J Urol 1995; 154: 4248
  • 23
    Goldenberg SL, Klotz LH, Srigley J et al. Randomized, prospective, controlled study comparing radical prostate-ctomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. J Urol 1996; 156: 8737
  • 24
    Dalkin BL, Ahmann FR, Nagle R, Johnson C. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. J Urol 1966; 155: 135760
  • 25
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 15917
  • 26
    Fair WR, Betancourt JE. Update on Memorial Sloan-Kettering cancer center studies of neoadjuvant hormonal therapy for prostate cancer. Mol Urol 2000; 4: 2418
  • 27
    Meyer F, Moore L, Bairati I, Lacombe L, Tetu B, Fradet Y. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. J Urol 1999; 162: 20248
  • 28
    Murphy WM, Soloway MS, Barrows GH. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 1991; 68: 8218
  • 29
    Hellström M, Häggman M, Bränstedt S et al. Histopathological changes in androgen-deprived localized prostate cancer. Eur Urol 1993; 24: 4615
  • 30
    Bazinet M, Zheng W, Begin LR, Aprikian AG, Karakiewicz PI, Elhilali MM. Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology 1997; 49: 7215
  • 31
    Gleave ME, La Bianca SE, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Long-term neoadjuvant hormone therapy prior to radical prostatectomy. evaluation of risk for biochemical recurrence at 5-year follow-up. Urology 2000; 56: 28994
  • 32
    Klotz L, Gleave M, Goldenberg SL. Neoadjuvant horm-one therapy: the Canadian trials. Mol Urol 2000; 4: 2337

Authors

  1. Authors

G. Aus, MD, Associate Professor.

P.-A. Abrahamsson, MD, Professor.

G. Ahlgren, MD, PhD.

J. Hugosson, MD, Professor.

S. Lundberg, MD.

M. Schain, MD.

S. Schelin, MD.

K. Pedersen, MD, PhD.

Abbreviation
NHT

neoadjuvant hormonal treatment

RP

radical prostatectomy.